Cocrystal Pharma Stock Performance
| COCP Stock | USD 0.96 0.00 0.000002% |
The firm shows a Beta (market volatility) of 1.79, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cocrystal Pharma will likely underperform. At this point, Cocrystal Pharma has a negative expected return of -0.0264%. Please make sure to confirm Cocrystal Pharma's information ratio, as well as the relationship between the skewness and relative strength index , to decide if Cocrystal Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cocrystal Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Cocrystal Pharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Last Split Factor 1:12 | Dividend Date 2018-01-24 | Last Split Date 2022-10-11 |
1 | What is Zacks Small Caps Estimate for COCP FY2025 Earnings | 11/20/2025 |
2 | Acquisition by Martin James Joseph of 300000 shares of Cocrystal Pharma at 0.42 subject to Rule 16b-3 | 11/24/2025 |
3 | Acquisition by Frost Phillip Md Et Al of 1500 shares of Cocrystal Pharma at 1.0 subject to Rule 16b-3 | 11/26/2025 |
4 | Cocrystal Pharma to Present at the Noble Capital Markets 21st Emerging Growth Equity Conference | 12/01/2025 |
5 | Why Cocrystal Pharma Inc. stock is a must watch in 2025 - Market Trend Review Real-Time Buy Signal Alerts - | 12/18/2025 |
6 | Acquisition by Frost Phillip Md Et Al of 25000 shares of Cocrystal Pharma at 0.9703 subject to Rule 16b-3 | 12/24/2025 |
7 | Acquisition by Frost Phillip Md Et Al of 40000 shares of Cocrystal Pharma at 0.9736 subject to Rule 16b-3 | 12/26/2025 |
8 | Acquisition by Frost Phillip Md Et Al of 20000 shares of Cocrystal Pharma at 0.9655 subject to Rule 16b-3 | 12/30/2025 |
9 | Acquisition by Frost Phillip Md Et Al of 50000 shares of Cocrystal Pharma at 0.9455 subject to Rule 16b-3 | 12/31/2025 |
10 | Will Cocrystal Pharma Inc. stock outperform Nasdaq index - Quarterly Trade Summary High Accuracy Investment Entry Signals - ulpravda.ru | 01/08/2026 |
11 | Acquisition by Rubin Steven D of 16410 shares of Cocrystal Pharma at 1.1 subject to Rule 16b-3 | 01/09/2026 |
12 | Cocrystal Pharma Grants Stock Options Under 2025 Incentive Plan - TipRanks | 01/15/2026 |
| Begin Period Cash Flow | 26.4 M | |
| Total Cashflows From Investing Activities | -8000.00 |
Cocrystal | Build AI portfolio with Cocrystal Stock |
Cocrystal Pharma Relative Risk vs. Return Landscape
If you would invest 101.00 in Cocrystal Pharma on November 6, 2025 and sell it today you would lose (5.00) from holding Cocrystal Pharma or give up 4.95% of portfolio value over 90 days. Cocrystal Pharma is currently does not generate positive expected returns and assumes 3.4731% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Cocrystal, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cocrystal Pharma Target Price Odds to finish over Current Price
The tendency of Cocrystal Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.96 | 90 days | 0.96 | about 89.56 |
Based on a normal probability distribution, the odds of Cocrystal Pharma to move above the current price in 90 days from now is about 89.56 (This Cocrystal Pharma probability density function shows the probability of Cocrystal Stock to fall within a particular range of prices over 90 days) .
Cocrystal Pharma Price Density |
| Price |
Predictive Modules for Cocrystal Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cocrystal Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cocrystal Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cocrystal Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cocrystal Pharma is not an exception. The market had few large corrections towards the Cocrystal Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cocrystal Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cocrystal Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.19 | |
β | Beta against Dow Jones | 1.79 | |
σ | Overall volatility | 0.06 | |
Ir | Information ratio | -0.05 |
Cocrystal Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cocrystal Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cocrystal Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cocrystal Pharma generated a negative expected return over the last 90 days | |
| Cocrystal Pharma has some characteristics of a very speculative penny stock | |
| Cocrystal Pharma has high historical volatility and very poor performance | |
| Cocrystal Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (17.5 M) with loss before overhead, payroll, taxes, and interest of (5.47 M). | |
| Cocrystal Pharma currently holds about 51.03 M in cash with (16.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Cocrystal Pharma Grants Stock Options Under 2025 Incentive Plan - TipRanks |
Cocrystal Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cocrystal Stock often depends not only on the future outlook of the current and potential Cocrystal Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cocrystal Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 10.2 M | |
| Cash And Short Term Investments | 9.9 M |
Cocrystal Pharma Fundamentals Growth
Cocrystal Stock prices reflect investors' perceptions of the future prospects and financial health of Cocrystal Pharma, and Cocrystal Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cocrystal Stock performance.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 7.64 M | ||||
| Shares Outstanding | 13.78 M | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 1.78 X | ||||
| Price To Sales | 92.45 X | ||||
| Gross Profit | (5.47 M) | ||||
| EBITDA | (17.75 M) | ||||
| Net Income | (17.5 M) | ||||
| Cash And Equivalents | 51.03 M | ||||
| Cash Per Share | 6.28 X | ||||
| Total Debt | 1.81 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 18.34 X | ||||
| Book Value Per Share | 0.59 X | ||||
| Cash Flow From Operations | (16.48 M) | ||||
| Earnings Per Share | (0.93) X | ||||
| Market Capitalization | 13.51 M | ||||
| Total Asset | 13.46 M | ||||
| Retained Earnings | (333.42 M) | ||||
| Working Capital | 9.15 M | ||||
| Current Asset | 6.75 M | ||||
| Current Liabilities | 3.15 M | ||||
About Cocrystal Pharma Performance
Assessing Cocrystal Pharma's fundamental ratios provides investors with valuable insights into Cocrystal Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cocrystal Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 94.32 | 64.57 | |
| Return On Tangible Assets | (1.50) | (1.57) | |
| Return On Capital Employed | (1.46) | (1.53) | |
| Return On Assets | (1.50) | (1.57) | |
| Return On Equity | (2.11) | (2.01) |
Things to note about Cocrystal Pharma performance evaluation
Checking the ongoing alerts about Cocrystal Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cocrystal Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cocrystal Pharma generated a negative expected return over the last 90 days | |
| Cocrystal Pharma has some characteristics of a very speculative penny stock | |
| Cocrystal Pharma has high historical volatility and very poor performance | |
| Cocrystal Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (17.5 M) with loss before overhead, payroll, taxes, and interest of (5.47 M). | |
| Cocrystal Pharma currently holds about 51.03 M in cash with (16.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Cocrystal Pharma Grants Stock Options Under 2025 Incentive Plan - TipRanks |
- Analyzing Cocrystal Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cocrystal Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Cocrystal Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cocrystal Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cocrystal Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cocrystal Pharma's stock. These opinions can provide insight into Cocrystal Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.